Strain Information | |
---|---|
Image | |
BRC No. | RBRC01869 |
Type | Targeted Mutation |
Species | Mus musculus |
Strain name | B6.129-Nod2<tm1Jhgt> |
Former Common name | Card15 KO (C57BL/6N background) |
H-2 Haplotype | |
ES Cell line | |
Background strain | |
Appearance | |
Strain development | Developed by Marco Giovannini, INSERM. PGK-hygromycin cassette was removed by cre recombinase. |
Strain description | This mouse was produced from the knock-in targeting of Card15 (Nod2) locus with EGFP cassette. The expression of the GFP is relatively low. C57BL/6 congenic (RBRC01869), C57BL/6 and 129 mixed background (RBRC01941). |
Colony maintenance | Homozygote x Homozygote |
References | CARD15/NOD2 is required for Peyer's patches homeostasis in mice. Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M, Foligne B, Ollendorff V, Heyman M, Bonacorsi S, Lesuffleur T, Sterkers G, Giovannini M, Hugot J P PLoS One, 2(6), e523 (2007). 17565376 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
EGFP | Enhanced Green Fluorescent Protein (Aequorea victoria) | 8 | EGFP | more 1 Diseases | |||
Nod2 | nucleotide-binding oligomerization domain containing 2 | 8 | Nod2 | more 1 Diseases | |||
loxP | phage P1 loxP | 8 | loxP | more 1 Diseases |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | more 9 phenotypes |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | jellyfish EGFP cDNA, SV40 polyA, Phage P1 loxP site, mouse Nod2 genomic DNA |
Research application | Cre/loxP system Fluorescent Proteins/lacZ System Immunology and Inflammation Research Internal/Organ Research Mouse Models for Human Disease |
Specific Term and Conditions | In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use. RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention. In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. |
Depositor | Marco Giovannini (INSERM) |
Strain Status | Frozen embryos |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- Mouse of the Month Jun 2007 |
BRC mice in Publications |
---|
Zong J, Salim M, Zhou H, Bian ZY, Dai J, Yuan Y, Deng W, Zhang JY, Zhang R, Wu QQ, Tang QZ. NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload. Lab Invest 93(10) 1128-36(2013) 23958879 |